Beyond the Steroid Ceiling: Modern Advances in IBD Management

Prof. Dr. Binod Karki at Gastro Core 2.0, Bhairahawa

Liver and Digestive Disease Center (LDDC) proudly highlights the academic participation of Prof. Dr. Binod Karki, who presented at the Gastro Core 2.0 Conference 2026, held at Tiger Palace Resort, Bhairahawa.

His presentation focused on:

“Beyond the Steroid Ceiling: The Rise of Small Molecules in Modern Inflammatory Bowel Disease (IBD) Management”

The session explored emerging therapeutic advancements in IBD, particularly the evolving role of small molecule therapies in patients with moderate to severe disease.

Shifting Paradigms in IBD Treatment

Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, has traditionally relied on corticosteroids and biologic therapies for disease control.

However, long-term steroid use is limited by safety concerns, often referred to as the “steroid ceiling.”

Dr. Karki’s presentation highlighted how modern treatment is moving beyond this limitation through:

• Introduction of small molecule therapies
• Improved oral treatment options for IBD
• Targeted immunomodulation approaches
• Personalized treatment strategies based on disease severity
• Reduced dependency on long-term steroid use

Small Molecules: A New Era in IBD Care

The presentation emphasized the growing importance of small molecule drugs in clinical practice, offering:

• Faster onset of action
• Oral administration convenience
• Targeted immune pathway modulation
• Potential for improved long-term disease control

These advancements represent a significant shift in how clinicians approach chronic inflammatory bowel conditions.

Clinical Relevance in Nepal

As IBD cases continue to rise in South Asia, access to advanced and sustainable treatment options is increasingly important.

Dr. Karki’s discussion reinforced the need for:

• Early diagnosis of IBD
• Individualized treatment planning
• Adoption of updated international guidelines
• Strengthening specialist gastroenterology services in Nepal

Conclusion

The evolution of IBD management beyond traditional steroid-based therapy marks a major milestone in gastroenterology.

Through academic contributions like this, LDDC continues to support innovation, education, and evidence-based advancement in digestive disease care in Nepal.